POI |
Primary ovarian insufficiency |
ASCO |
American Society of Clinical Oncology |
HFEA |
Human Fertilization and Embryology Authority |
ASRM |
American Society for Reproductive Medicine |
CMF |
Cyclophosphamide, methotrexate, fluorouracil |
CEF |
Cyclophosphamide, epirubicin, fluorouracil |
CAF |
Cyclophosphamide, doxorubicin (Adriamycin), fluorouracil |
AC |
Doxorubicin (Adriamycin), cyclophosphamide |
ABVD |
doxorubicin/bleomycin/vinblastin/dacarbazine |
CHOP |
cyclophosphamide/doxorubicin/vincristine/prednisone |
CVP |
cyclophosphamide/vincristine/prednisone |
AML |
Acute myeloid leukemia |
ALL |
Acute lymphoblastic leukemia |
DSB |
Double-strand break |
PI3K/AKT/FOXO3a |
Phosphoinositide 3-kinase/protein kinase B/forkhead box protein O3a |
GnRH |
Gonadotropin-releasing hormone |
OSC |
Ovarian stem cell |
IVF |
In vitro fertilization |
UK |
United Kingdom |
NICE |
National Institute for Health and Care Excellence |
IVM |
In vitro maturation |
PCOS |
Polycystic ovarian syndrome |
ART |
Assisted reproductive technology |